The top analyst upgrades, downgrades and other research calls from Wednesday included Altice, Blue Apron, CubeSmart, Horizon Pharma, KB Home, Las Vegas Sands, Mylan and Switch.
La Jolla Pharmaceutical and Sarepta Therapeutics are among seven biotech stocks that have seen some notable insider trading recently.
Athenex led biotech stocks higher on Wednesday after its Chinese subsidiary submitted an Investigational New Drug application to the China Food and Drug Administration.
As many as nine IPOs may hit the public markets this week, led by cable and broadband provider Altice.
Athenex expects to price 6 million shares in the range of $11 to $13 apiece for an initial public offering is valued up to more than $89 million.
Athenex has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).